Replies to post #178021 on Biotech Values

[caravon]

It appears that anti – PD-L1 antibody and EGFR inhibitor (like CO-1686 from CLVS) combo drugs are very promising in NSCLC.

[jq1234]

I don't think it is taking market share question as PD1 might have difficulty proving better than targeted therapies for EGFRm and ALK+ NSCLC based on results we have seen so far, rather potential combination usage. Roche might agree with correlation view as it is the first company to combine its PDL1 with erlotinib for EGFRm and MEKi cobimetinib for KRAS.